Trial · NCT06903884
3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
NCT06903884, Phase 3, Recruiting, The University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis. Trials, record NCT06903884. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06903884
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
- NCT number
- NCT06903884
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 94 participants, estimated
- Lead sponsor
- The University of Hong Kong
- Conditions
- Vernal Keratoconjunctivitis
- Interventions
- 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic ophthalmic emulsion
- First posted
- 2025-04-01
- Last updated
- 2026-11-09
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Cornea Fluorescein Staining (CFS) score from baseline to 4 weeks, 8 weeks and 16 weeks between study groups | From baseline to 4 months post- treatment between study groups | Higher values mean inferior outcomes. Graded according to the modified Oxford grading scale (range 0, 0.5, 1, 2, 3, 4, 5). A difference in score of at least 2 levels (i.e. 4 to 2) or complete resolution of staining (i.e. 0) are both considered clinically significant endpoints. |
| Secondary | Percentage of patients requiring rescue topical steroid therapy at 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | Number of patients requiring rescue topical steroid therapy divided by all patients participated in this study |
| Secondary | Percentage of patients with improvement in Cornea Fluorescein Staining (CSF) at 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | Number of patients with improvement in CFS requiring rescue topical steroid therapy divided by all patients participated in this study |
| Secondary | Change in best corrected visual acuity from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | From logmar(1.0 to -0.1) |
| Secondary | Change in Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) score from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | Range from 0-28, one mark was collected per patient, with higher scores meaning worse |
| Secondary | Change in Quality of Life in Children with Vernal Keratoconjunctivitis (QUICK) score from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | Range from 0-48, one mark was collected per patient, with higher scores meaning worse outcomes |
| Secondary | Change in NIKBUT from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | NIKBUT is measured in seconds and average of 3 consecutive readings is taken. Higher values mean better outcomes. |
| Secondary | Change in tear meniscus height from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | In millimetres. Readings serve as objective parameters for tear volume |
| Secondary | Change in tear cytokines from baseline to 4 weeks, 8 weeks and 16 weeks | From baseline to 4 months post- treatment between study groups | Percentage change in tear cytokines analysis done in lab |
| Other | Incidence of ocular adverse events | From baseline to 4 months post- treatment between study groups | Number of patients with ocular adverse events divided by all patients participated in this study |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers39
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06903884
GET https://conductscience.org/api/trials/v1/NCT06903884/papers?page=2